Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:2/19/2009

er 31, 2008, was $1.9 million (or $0.06 per share) and $30.7 million (or $0.93 per share), respectively, compared with a net loss of $9.9 million (or $0.30 per share) and $38.2 million (or $1.29 per share) for the same periods in 2007. At December 31, 2008, ISTA had cash and short-term investments of $53.0 million.

2009 Financial Outlook

  • We expect our net revenue for 2009 will be approximately $92 to $97 million. We do not expect a generic to Xibrom in 2009. Our net sales are seasonal, with first quarter net sales typically being the lowest of the year and less than the prior quarter.
  • We expect our gross margin to be 70% to 73% in 2009. We expect our gross margin to be at the lower end at the beginning of the year and increasing to the higher end by year end 2009, due to the timing of certain manufacturing expenses in 2009.
  • We expect to be approximately operating income breakeven in 2009.
  • We expect our net loss for 2009 will be approximately $7 to $10 million, due to interest and related expenses.
  • Depending upon the progress of our clinical and pre-clinical programs, we expect our research and development expenses in 2009 to be in the range of $20 to $25 million and include costs associated with supporting the Bepreve NDA filing, milestones we have paid or expect to pay to Senju for the acceptance and approval of Bepreve, the Xibrom QD confirmatory study, T-Pred study completion, and a low-concentration version of Xibrom for dry eye.
  • We expect to end 2009 with a cash balance of $35 to $45 million, including cash drawn on our Silicon Valley Bank revolving credit facility, subject to change due to fluctuations in working capital.

Conference Call

ISTA will host a conference call with a simultaneous webcast today, February 19, 2009, at 5:00 PM Eastern Time, to discuss its fourth qu
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Mary Ann Thompson and Mathieu Nikel decided it was time to ... their son, Isaac, said there was only one choice for them ... 2001 when Thompson was an undergraduate student and needed a French ... time, was French and so she asked him. , ... when she was 7 years old. Nikel is originally from ...
(Date:9/18/2014)... Kent, WA Chiropractor Danene Saggau ... to announce that Dawn Kelly has agreed to become the ... looks forward to Ms. Kelly expanding her role within the ... her a key contributor. “ Dawn Kelly brings to ... personal experiences that will allow me to focus on ...
(Date:9/18/2014)... 2014 Memorial Cardiac and Vascular ... week by performing the first ever, adult heart transplant ... for Organ Sharing) approval to launch the adult heart ... two programs in South Florida. , The skilled ... Gongora, Medical Director of the Adult Heart Transplant ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Exposure to diverse communities ... study. Hearing different languages in the park ... to learn from people who are different from them, ... like adults, are often biased against interacting with and ... Amanda Woodward, a University of Chicago psychology professor, said ...
(Date:9/18/2014)... By Steven Reinberg HealthDay ... a sign that the Ebola outbreak in West Africa is starting ... that more than 700 new cases of the deadly viral infection ... number of cases to more than 5,300, with roughly half of ... reported. The number of deaths now tops 2,600. WHO ...
Breaking Medicine News(10 mins):Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3
... of low health literacy the difference between patients, ... effectively communicate complex medical information is $106 billion ... biopharmaceutical company. To improve the health literacy of professionals ... health literacy study emphasis beginning this fall. The MU ...
... , ... Government Agencies to Increase ROI of IT Infrastructure , ... Reston, VA (PRWEB) February 18, 2010 -- Carahsoft ... Parabonâ Computation , a veteran provider of extreme-scale grid computing software and services. ...
... ... software standardization program at seven hospital laboratories of the Cleveland Clinic in Ohio. ... ... healthcare diagnostic information technology and outreach solutions, has successfully completed system-wide implementation of ...
... Rat studies suggest Victoza could spur rare thyroid tumor, ... THURSDAY, Feb. 18 (HealthDay News) -- The U.S. Food ... January to approve a new diabetes drug, Victoza (liraglutide), ... risk for a rare thyroid cancer. , Victoza, among ...
... (Feb. 17, 2010) Van Andel Research Institute ... sunitinib, a treatment that is currently the first line of ... form of kidney cancer. Most patients who show a ... after one year of treatment. Kidney cancer is among ...
... , ST. PETERS, Mo. , Feb. 18 ... Electronic Materials, Inc., has donated $25,000 to Meds & ... charity dedicated to saving the lives of Haiti ,s malnourished ... Kids produces peanut-based ready-to-use therapeutic food (RUTF) – known in ...
Cached Medicine News:Health News:MU offers training program to improve health literacy 2Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 2Health News:Parabon's Frontier Grid Platform Software Now Available on Carahsoft's GSA Schedule 3Health News:Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories 2Health News:FDA Approved Diabetes Drug Despite Hints at Cancer Risk 2Health News:FDA Approved Diabetes Drug Despite Hints at Cancer Risk 3Health News:VARI findings may help patients with deadly kidney cancer 2Health News:MEMC Foundation Donates to Help Fight Malnourishment in Haiti 2Health News:MEMC Foundation Donates to Help Fight Malnourishment in Haiti 3
(Date:9/18/2014)... 2014  Low T Center endorses the recommendations ... Hyattsville, Maryland earlier this week. The ... patient population for testosterone therapy (TRT), as well ... TRT. Examining recent claims from studies that TRT affects ... studies do not provide convincing evidence that TRT ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014 /PRNewswire/ ... innovative laboratory technologies and products to hospitals, ... announced today an amended distributorship agreement with ... reagents, controls and instruments, including the Sysmex ... Sysmex XP-300™, XT-Series and XN-Series Automated Hematology ...
(Date:9/18/2014)... Research and Markets  has announced the addition of ... Columns Market" report to their offering. ... enantiomers of the same compound with different affinities for ... possessing different elution times. Chiral stationary phases are generally ... chiral separation chromatography columns market is growing at a ...
Breaking Medicine Technology:Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Micro Market Monitor: Global Chiral Separation Columns Market 2
... Feb. 7, 2011 Beckman Coulter, Inc. (NYSE: ... and marketer of products that simplify, automate and ... technology leader that designs, manufactures, and markets innovative ... commercial customers, announced today that they have entered ...
... (Nasdaq: GXDX ) announced today that the Federal ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Novartis to purchase all outstanding shares of common stock of ... the HSR Act waiting period satisfies one of the conditions ...
Cached Medicine Technology:Danaher to Acquire Beckman Coulter, Inc. 2Danaher to Acquire Beckman Coulter, Inc. 3Danaher to Acquire Beckman Coulter, Inc. 4Danaher to Acquire Beckman Coulter, Inc. 5FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act 2
ELISA Test System for the detection of HBc...
Test for Anti-HBc for use on the Abbott Prism...
... flexible meter for Point of ... Accu-Chek Inform System offers user-friendly, ... the only Point of Care ... the entry and automatic transfer ...
... Introducing BenchMark XT® the only ... the flexibility you need to expand ... and improve your slide turnaround time. ... You choose how to use the ...
Medicine Products: